Heron Therapeutics, Inc. (NASDAQ:HRTX) Shares Acquired by Clearline Capital LP

Clearline Capital LP boosted its holdings in Heron Therapeutics, Inc. (NASDAQ:HRTX) by 48.9% during the 3rd quarter, HoldingsChannel reports. The institutional investor owned 2,226,512 shares of the biotechnology company’s stock after purchasing an additional 731,246 shares during the quarter. Clearline Capital LP’s holdings in Heron Therapeutics were worth $4,431,000 at the end of the most recent quarter.

Other hedge funds have also made changes to their positions in the company. nVerses Capital LLC purchased a new stake in shares of Heron Therapeutics in the second quarter worth about $27,000. HB Wealth Management LLC purchased a new stake in Heron Therapeutics during the 2nd quarter worth approximately $35,000. B. Riley Wealth Advisors Inc. purchased a new position in shares of Heron Therapeutics during the 2nd quarter valued at approximately $41,000. Sei Investments Co. acquired a new stake in Heron Therapeutics in the second quarter valued at $44,000. Finally, Valeo Financial Advisors LLC acquired a new position in Heron Therapeutics during the 2nd quarter worth $45,000. Hedge funds and other institutional investors own 80.01% of the company’s stock.

Heron Therapeutics Stock Performance

Shares of HRTX stock opened at $1.19 on Monday. The firm has a market capitalization of $181.00 million, a PE ratio of -6.61 and a beta of 1.81. The stock has a fifty day moving average of $1.67 and a two-hundred day moving average of $2.40. Heron Therapeutics, Inc. has a 1 year low of $1.04 and a 1 year high of $3.93.

Heron Therapeutics (NASDAQ:HRTX) last announced its earnings results on Tuesday, November 12th. The biotechnology company reported ($0.03) EPS for the quarter, hitting the consensus estimate of ($0.03). The firm had revenue of $32.81 million for the quarter, compared to the consensus estimate of $36.40 million. During the same period in the previous year, the firm earned ($0.17) EPS. Equities research analysts predict that Heron Therapeutics, Inc. will post -0.13 earnings per share for the current fiscal year.

Analysts Set New Price Targets

A number of research firms recently commented on HRTX. StockNews.com downgraded Heron Therapeutics from a “buy” rating to a “hold” rating in a research note on Thursday, November 21st. Needham & Company LLC lowered their price objective on shares of Heron Therapeutics from $5.00 to $4.00 and set a “buy” rating for the company in a research report on Wednesday, November 13th.

Heron Therapeutics Profile

Heron Therapeutics, Inc, a commercial-stage biotechnology company, focuses on enhancing the lives of patients by developing and commercializing therapeutic that enhances medical care. The company's product candidates utilize its proprietary Biochronomer, a drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration.